Novel therapeutic strategies for recurrent SCLC

Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.

Automated summary

The limited therapeutic options and poor prognosis for patients with relapsed small cell lung cancer are discussed in this review. Although there have been modest improvements in clinical outcomes with the introduction of immunotherapy in frontline treatment, treatment in the second-line setting has remained largely unchanged. The review also addresses current treatment options, recent advances in molecular biology, emerging therapeutic options, and potential strategies to improve clinical outcomes for these patients.